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Improving Health Outcomes for Patients with Depression:
A Population Health Imperative.
Report on an Expert Panel Meeting
Janice L. Clarke, RN,1 Alexis Skoufalos, EdD,1 Alice Medalia, PhD,2 and A. Mark Fendrick, MD3
Editorial
A Call to Action
David B. Nash, MD, MBA
Our knowledge of physical ailments is growing expo-
nentially and innovative treatments continue to advance at
breakneck speed. In comparison, behavioral health disorders
seem to be shrouded in mystery; the science is still evolving
and commonly prescribed treatments are often ineffective.
This is the case even though mental disorders now top the list
of the most costly conditions in the United States.1
As an internist, I’m aware that some of my patients with
chronic conditions also have symptoms of depression. Never-
theless, I was astonished to learn that up to one-quarter of
primary care office visits involve depression and that, de-
spite a lack of appropriate training, primary care providers
deliver half of all behavioral health services in the United
States. Given the dearth of behavioral health specialists –
especially in non-urban areas – this should not have come as
such a surprise.
A closer inspection of our health care system reveals that
the historical separation of physical and behavioral health
care compromises care and intensifies problems for patients
with serious mental illness in several ways:
 Separate facilities and locations for physical and be-
havioral health care impede easy access to treatment.
 Separate funding streams for physical and behavioral
health services create financial barriers to appropriate
care.
 Difficulty in sharing information and expertise across
the separate systems hinders effective care coordi-
nation.
 The tendency of clinicians to focus on specific physical
or behavioral symptoms and disorders rather than on
the person experiencing the problem leads to subopti-
mal outcomes.2
With health reforms taking effect, the health system is
evolving in positive ways. First, we are beginning a slow but
deliberate transformation from segregated to integrated be-
havioral health services. Secondly, we are entering a new
era in which ‘‘value’’ will supplant volume and the con-
versation is shifting from how much we spend to how well
we spend resources for these services.
As a discipline, population health is at the confluence of
changes that are taking place across the health care land-
scape. Holistic by nature, it recognizes and incorporates
social and environmental factors that have a profound effect
on overall health and well-being. A population framework
seems an ideal vehicle for optimizing the care of patients
and understanding where behavioral health fits in the broader
context of the Triple Aim.
This will not be an easy task. It will take focused, well-
coordinated efforts; for example:
 Long-term institutional care issues must be resolved.
 The National Academy of Medicine (formerly the
Institute of Medicine) must develop and adopt mea-
sures focused on health outcomes in addition to pro-
cesses.
 The behavioral health community must become a more
active agent of positive change.
The expert panel meeting on which this supplement is
based left me with no doubt that a new call to action is
imperative. The time is right for all stakeholders – con-
sumers, the health care industry, and legislators – to act and
put forward a new agenda for behavioral health and an in-
tegrated vision of the US health care system.
Introduction
Today, millions of Americans are diagnosed with ma-
jor depressive disorder, a condition that seriously impairs
functional ability and frequently compromises physical
health. The burden of this pervasive illness is high and the
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associated consequences have a negative impact, not only
for patients, but also their family members, employers, and
communities.
Progress toward full implementation of the Affordable
Care Act (ACA) has served as the impetus for transforma-
tive change across the US health care system. Once segre-
gated and subjected to carve-outs and benefit limitations,
behavioral health (BH) services are being integrated into the
full continuum of care. Now that their organizations are held
accountable for reducing costs, increasing access, and im-
proving health outcomes, health system leaders are working
to better understand the needs of the patient populations they
serve. Although there are high expectations for improve-
ment in clinical outcomes, new delivery paradigms such as
Accountable Care Organizations (ACOs) and patient-
centered medical homes (PCMHs) are typically ill-equipped
to provide BH services.
The quality of all health care is impacted by systemic
issues, and all stakeholders must be positioned to share in-
formation and resources to serve the populations for whom
they are responsible and accountable. Understanding the
various issues and challenges from diverse perspectives—
patients and patient advocates, physical and mental health
professionals, community service agencies, payers, policy
makers—is key to developing an effective strategy for im-
proving the US mental health system model.
On November 3, 2015, the Jefferson College of Popula-
tion Health, Takeda Pharmaceuticals, and Lundbeck LLC
convened a multidisciplinary expert panel (Table 1) to
explore the critical issues and articulate potential solutions
for improving individual patient and population health
outcomes for depressive disorders. The following report
synthesizes the panelists’ presentations, discussions, and
recommendations. Critical issues and value-based solu-
tions are listed in Table 2.
Overview: Depression and the Population
Health Imperative
The World Health Organization recognizes major de-
pression as the leading cause of disability globally and ranks
it fourth among the leading causes of global disease burden.3
The impact of this reality on societies is profound; pro-
ductive years lost to disability from depression are 3 times
greater than from diabetes, 8 times greater than from heart
disease, and 40 times greater than from cancer.4
Mental illness is a major driver of health care costs in the
United States, where 1 in 4 people struggle with a BH or
substance abuse problem at some point in their lives.5 Vir-
tually no family is untouched.
Approximately 14.8 million Americans live with major
depression, and a closer look at its prevalence reveals an
especially disturbing picture:
 It is the leading BH diagnosis in the United States6 and
is relatively common in primary care settings where it
occurs in approximately 10% of patients.7
 It is very expensive, evidenced by 50%-100% higher
direct health care costs and indirect costs related to lost
productivity.8
 It is deadly, accounting for more than 30,000 suicides
per year.9
Table 1. Panel Participants (* = presenter)
Martin D. Cheatle, PhD
Director, Behavioral Medicine, PENN Pain Medicine
Center
Director, Pain and Chemical Dependency Research at the
Center for Studies of Addiction
University of Pennsylvania
Philadelphia, PA
A. Mark Fendrick, MD *
(Topic: Reducing the Per Capita Cost of Care)
Professor of Internal Medicine, School of Medicine
Professor of Health Management and Policy, School of
Public Health
University of Michigan
Ann Arbor, MI
Susan B. Frampton, PhD *
(Topic: Health Reform – Patient and Family Perspective)
President, Planetree
Derby, CT
Lynne R. Kornblatt, LLM, JD, RN
Chief Human Resources Officer
Einstein Healthcare Network
Philadelphia, PA
Alice Medalia, PhD *
(Topic: Cognitive Deficit in Affective Disorders)
Clinical Director of Cognitive Health Services, New York
State Office of Mental Health
Professor of Medical Psychology, Department of Psychiatry
and Director of Psychiatric Rehabilitation Services,
Columbia University
New York, NY
Garrett E. Moran, PhD *
(Topic: Critical Issues and Quality Gaps)
Vice President and Associate Director, Westat, Inc.
Director, Academy for the Integration of Behavioral Health
and Primary Care, Agency for Healthcare Research and
Quality
Rockville, MD
David W. Oslin, MD *
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Professor of Psychiatry
Corporal Michael J. Crescenz Veterans Affairs Medical
Center and the University of Pennsylvania
Philadelphia, PA
Stephen J. Paolucci, MD
Chief Medical Officer, Geisinger Bloomsburg Hospital
Chairman of Psychiatry, Geisinger Medical Center
Danville, PA
Barry W. Rovner, MD
Professor of Psychiatry, Neurology and Ophthalmology
Thomas Jefferson University
Philadelphia, PA
Byron C. Scott, MD, MBA *
(Topic: Employer Perspective)
Associate Chief Medical Officer
Truven Health Analytics
Chicago, IL
Michael J. Vergare, MD
Senior Vice President of Academic Affairs
Thomas Jefferson University
Philadelphia, PA
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Untreated or inadequately treated BH conditions are
major drivers of suicide. In 2011 alone, US statistics reveal
that there was 1 suicide every 14 minutes; this translates to
41,149 deaths – more deaths than from homicides or motor
vehicle accidents.10 A large percentage of suicides are asso-
ciated with people suffering from a combination of chronic
pain and depression. Clearly, these tragedies might be pre-
vented by better access to the right care at the right time.
However, despite major scientific breakthroughs, techno-
logical and therapeutic advances and steady improvement in
the quality of care for physical health problems, care for BH
disorders in the United States continues to be shockingly
inadequate. Several complex, interrelated issues raise seri-
ous concerns:
Provider-related issues
Sixty percent of individuals suffering with BH conditions
receive no care at all and, of those who do receive care, only
20% are seen by a trained mental health professional. In
fact, two thirds of primary care providers (PCPs) report poor
access to referrals for BH services (including psychother-
apy, cognitive behavior therapy or individual/group/family
counseling) for their patients.
 Typical Care Setting - Most patients receive BH
treatment in primary care settings. Although PCPs de-
liver up to half of all BH services in the United States,11
most lack the appropriate training and diagnostic ex-
pertise to recognize and/or effectively treat comorbid
BH problems.12 Consequently, they deliver even min-
imally adequate BH care only 12.7% of the time13; and
of the 30 million patients who receive a prescription for
a psychiatric medication in a primary care setting, only
25% improve.12
 Current Outcomes of Care - The evidence shows that
‘‘usual care’’ for depression is woefully ineffective.
Research findings reveal that treatment response rates
range from 26%-63% and remission rates range from
11%-47%.14,15,16 Under clinical trial conditions, 55%-
65% of patients showed improvement with an average
of 12.7 psychotherapy sessions; however, a study con-
ducted under real-world conditions revealed that 30% of
patients stop treatment after the first session, 15%-25%
‘‘improve’’ and only 5%-10% ‘‘recover’’17 (Table 3).
 Supply of BH Professionals - A significant barrier to
access exists because of a dire shortage of BH profes-
sionals; nation-wide, there is only 51% of the needed
Table 2. Critical Issues and Potential Solutions
Critical Issues Potential Solutions
Fragmentation Integration
General fragmentation in clinical systems
and care delivery settings
Multistakeholder approaches
Separate reimbursement structures for physical
and behavioral health (BH) services
Integrated care delivery systems
Separation of physical and BH services
and claims by health insurers
Value-based health insurance designs
Knowledge Gaps Education
BH clinical knowledge and process gaps,
particularly among primary care providers (PCPs)
Assure that PCPs receive strong foundation courses in BH
(eg, screening for depression and cognition problems)
Lack of understanding of BH among employers Educate employers to recognize signs of depression
in employees and provide services when needed
Lack of patient/family understanding of
BH conditions and involvement in care decisions
Educate patients, their families and caregivers about
BH conditions and treatment alternatives
Barriers to patient access Accessibility
Insufficient BH specialty providers Increase the number and broaden the
distribution of BH specialty cliniciansInadequate distribution of BH specialists
Table 3. How Effective Is ‘‘Usual Care’’
for Depression?
Population
Response
rate (%)
Remission
rate (%)
Research Studies
Clinical trials
(antidepressant
efficacy studies)
(Thase ME, et al,
J Clin Psych
2005;66:974–981)
63% 47%
STAR-D: initial treatment
(effectiveness study)
(Trivedi et al, Am J
Psychiatry 2006;163:28–40)
47% 33%
Real World
Private practice psychiatry
(Katzelnick D et al,
Psych Services
2011;62:929–935)
36% 18%
Public sector mental
health outpatients
(Rush AJ et al,
Biol Psych 2004;56:46–53)
26% 11%
STAR-D = sequenced treatment alternatives to relieve depression.
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capacity.18 BH professionals are generally concentrated
in large urban areas, and more than half of the counties
in the U.S. do not have a single practicing BH pro-
fessional.19 Also, far too many BH professionals are not
available to patients covered under Medicare or Med-
icaid insurance largely because of low reimbursement
rates. Typically, any access for these patients is limited
to inexperienced and/or poorly trained providers, fur-
ther compromising their ability to receive appropriate
care. Conventional wisdom holds that only the very
wealthy or the very poor can afford BH.
People with serious mental illnesses tend to die many
years younger than their counterparts without these condi-
tions. Because the interface between physical health care
providers and BH specialists is generally weak, patients with
comorbid chronic health problems often receive inadequate
treatment.20 Moreover, key population subgroups (eg, el-
derly, some minorities) may resist being referred to the BH
specialty sector for treatment.12
Health system-related issues
Historically separate systems for treatment of physical
and BH conditions are at the root of many serious problems.
For example:
 Capacity - Currently, neither system has the capacity to
adequately treat depression and other common BH dis-
orders. The BH system is lacking in the number and
distribution of providers; PCPs lack the necessary skill set
to appropriately screen, diagnose, and treat BH conditions
and have difficulty finding BH specialists for referrals.
 Structural differences – Physical and BH organizational
structures and patient safety cultures differ, and com-
munication among providers in the 2 systems is often
lacking or poor at best.
 Funding and reimbursement – Separate physical and
BH funding streams create significant barriers to access
and care coordination. Fee-for-service payment creates
the wrong incentives. Importantly, health insurance
discrimination related to BH disorders remains a
chronic problem that is only beginning to yield to parity
and ACA laws.
The current BH delivery system is fraught with problems;
for example, the system is not structured for efficient use,
and current training practices do not prepare incoming
professionals to meet the requirements necessary for treating
patients in an integrated system. These inefficiencies are
costly. Clinical care accounts for only 20% of health out-
comes.21 A recent study found that having any BH diagnosis
was associated with a 3.5 times higher treatment cost, and
that cost savings of $26-$46 billion per year could be at-
tained through effective integration of medical and behav-
ioral services.22
In summary, there are multiple issues and quality gaps in
urgent need of solutions. Because of the historical separa-
tion of BH and general medical/primary care systems, nei-
ther system has sufficient capacity to treat patients who
present with BH conditions. Segregated funding and insur-
ance discrimination make it difficult to pay for and coor-
dinate care. The stigma associated with BH conditions and
discrimination against those with BH problems results in
reluctance to seek treatment, particularly in specialty care
settings.23 Nationwide, there are shortages and inefficient
allocation /distribution of BH professionals, and inadequate
or nonexistent electronic BH records and registries make it
difficult to coordinate and manage the care of populations
with BH conditions.
Promoting Awareness of the Issues
and Opportunities for Improvement
Although the problems loom large, progress can be made
by means of targeted education for health care policy
makers, providers, employers, and patients. With increased
understanding of BH as a vital component of an individual’s
health and well-being, emerging solutions will be described
in the following sections.
Cognitive dysfunction in affective disorders
Multiple stakeholders (eg, primary care and BH special-
ist providers, employers, patients and their families) would
benefit from education regarding the functional conse-
quences of affective disorders, a set of psychiatric condi-
tions that are also known as mood disorders. The main types
of affective disorders are depression, bipolar disorder, and
anxiety disorder. Symptoms vary by individual and range
from mild to severe, but they typically affect mood. How-
ever, diagnostic symptoms account for surprisingly little
variance in everyday functional behaviors and contrib-
ute poorly to the prediction of the breadth and persistence
of functional impairment experienced by individuals with
mood disorders.24,25,26
A majority of individuals with major depressive disorder,
regardless of age, experience mild to moderate cognitive
impairment in several domains, most commonly in execu-
tive functions, memory and processing speed. The impair-
ment is most severe in chronic depressive illness, especially
when there is associated psychosis. However, even in the
absence of psychotic symptoms, 95% of people with uni-
polar depression have significant cognitive deficits after 8
weeks of antidepressant treatment, even when affective
symptoms have remitted.27 In bipolar disorder, significant
cognitive impairment often persists during the euthymic
state (ie, unrelated to mood). Cognitive deficits in affective
disorders are pervasive across multiple cognitive domains
and persistent throughout the course of the illness. Not only
are they present early in the course of illness but they are
highly predictive of functional disability.
Cognition involves attention, memory, processing speed,
and executive function (planning and organization). Most
jobs require processing speed and divided attention for do-
ing more than 1 task at a time (eg, a waiter must take a
customer’s order and acknowledge the next customer’s wish
for a check). Functioning is always impaired for an indi-
vidual with a cognitive deficit and is often misconstrued by
employers as laziness.
Individual underperformance related to a cognitive deficit
or dysfunction often occurs in academic settings (eg, fail-
ure to grasp course content) and hampers occupational
achievement, interpersonal relationships, community par-
ticipation and independent living (eg, forgetting to pay bills,
failure to take medication as directed). In fact, studies reveal
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that baseline cognitive functioning in attention, memory,
and executive function accounted for more than 25% of
variance in work and social functioning even after consid-
ering clinical symptoms; hence, cognitive functioning is
closely linked to performance in work or school settings.28–31
Typically, most clinicians use mental status exams only to
rule out neurologic conditions and other medical issues. It is
equally important to ask if a patient has difficulty with at-
tention, memory, organization, and planning in order to
rule in cognitive difficulties. Mini-Mental State Exams are
readily available, and overall treatment planning for func-
tional recovery must include cognitive training as well as
symptom management, medication, stress management, and
other aspects.
It is always useful for clinicians to know how the patient’s
brain is functioning (eg, whether or not a patient with dia-
betes is able to attend to a medication regime as well as
perform his or her job). Mental disorders are chronic con-
ditions that require ongoing care management with multiple
visits over time. For a patient with annual visits, a cognitive
assessment should be part of each visit. Every care profes-
sional can help by meeting each individual where he or she
is and by being sensitive to cognitive deficits.
When cognitive dysfunction is present (ie, evidence of
functional impairment or assessment reveals a deficit), the
therapeutic approach should always include psychoeduca-
tion, cognitive remediation and a review of the overall
treatment plan.
Critical role of employers in improving health outcomes
for employees with depression
Employers have become increasingly concerned by the
prevalence of depression among their employees and its
effect on their organizations. BH disorders generate billions
of dollars in direct and indirect costs for employers every
year (eg, employee assistance programs, disability claims,
lost productivity, absenteeism, work impairment) and, be-
cause depression is a common condition among employees
across all sectors, the National Business Group on Health
has targeted it for study.
The National Business Group on Health is an organiza-
tion of Fortune 500 companies and large public sector em-
ployers representing large employer perspectives on
national health policy issues. In 2014, the organization
partnered with Truven Health Analytics to collect, analyze,
and report on the Employer Measures of Productivity, Ab-
sence and Quality (EMPAQ), a set of 15 standardized
metrics that evaluate 3 aspects of a business’s human capital
investment: (1) incidence (how many use it), (2) cost, and
(3) lost workdays (impact on productivity).32 Of the more
than 100 employers who participated in the 2014 EMPAQ
report, 93% offered a health risk assessment (HRA).
Industry-wide, the employee participation rate was 49% and
rates correlated positively with increasing financial incen-
tives. Companies that offered a financial incentive averaged
57% participation compared to 21% participation for com-
panies that offered no financial incentive. With regard to
disability claims, employers who offered a stay-at-work
program with light duty or transitional assignments reduced
lost work days by 6% per 100 employees and reduced their
average long-term disability cost per claim by 33%. On-site
clinics (offered by 60% of employers) were associated with
a decreased incidence of absences.
Expert panelists observed that HRA results might be
useful in tailoring employer-sponsored programs for de-
pression; for instance, on-site employee assistance program
counseling and access to other programs could be expanded.
Senior leadership training could be expanded to include
recognition of signs of depression in employees. Importantly,
a vocabulary must be developed for more effective commu-
nication about mental health in the work environment.
The panelists agreed that employers’ health care leaders
must increase their business and emotional literacy con-
cerning BH issues and the struggles of individuals with
these conditions. Once the stigma of BH is removed, these
leaders can have meaningful discussions with employees.
BH screening should be an important part of a long-term
employer strategy.
Closing the BH professional and process gaps
Awareness does not provide the necessary impetus for
positive action. In addition to inadequate numbers and uneven
distribution of providers, closing the gaping BH professional
gap requires training and retaining more BH professionals in
the principles and processes of integrated health care (eg,
‘‘working smarter’’ and understanding that positive results
are not achievable within the typical ‘‘50-minute hour’’).
BH specialists must be leveraged more effectively
through clinical partnerships (especially with primary care)
and technology (eg, in some cases telemedicine is more ac-
cessible than face-to-face). Integration of BH care with primary
care fosters access to better care, improves health outcomes,
and lowers costs – the Triple Aim of health care reform.
A serious issue at the core of BH is one of diagnosis. In
order for a patient to be treated effectively, he or she must
be diagnosed correctly. Standardizing the process of diag-
nosis requires consensus regarding care for a patient with a
given diagnosis; unfortunately, the Diagnostic and Statis-
tical Manual of Mental Disorders fails to take individual
patient differences into account. Unlike its counterparts in
physical medicine, the process for ‘‘proven depression’’ has
yet to be conceptualized.
Achieving the Triple Aim for Patients
with Depressive Disorders
The venerable Institute for Healthcare Improvement believes
that new designs must be developed to simultaneously pursue 3
dimensions known as the ‘‘Triple Aim’’: (1) improving the
patient experience of care (including quality and satisfaction),
(2) improving the health of populations, and (3) reducing the per
capita cost of health care. It is likely that the framers of US
health care reform were influenced by the Triple Aim when they
drafted what became the ACA that promised high-quality, af-
fordable health care and better health outcomes for all Ameri-
cans at a lower cost. How have health reforms impacted these
dimensions in the context of BH and depression?
Improving the experience of care
for patients with depression
Despite broad recognition that patient-centered care is
important, patients often experience disenfranchisement—
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especially those with BH issues. When people are not
treated with basic dignity and respect by providers, they are
likely to avoid future interactions with those providers. Even
if care is safe, effective, and widely available, it is of little
value if patients choose not to use it.
The patient advocacy movement begun in the 1970s by
Planetree Founder, Angelica Thieriot, challenged the status
quo of patients as passive recipients of care by demanding
that patients be treated as competent adults and encouraged
to take an active part in their healing, and by insisting that
hospitals meet patients’ human need for respect, control, and
supportive care.33 Since that time, the definition of ‘‘patient-
centered’’ has evolved to ‘‘patient-and-family-centered,’’ a
clear understanding that the patient is not just a recipient of
care but rather a codesigner of care. This implies that the
treatment must match the patient’s goals and take into ac-
count the impact on his or her family. With implementation
of the ACA, the new patient mantra has become, ‘‘Nothing
about me without me.’’
Consider the following recent changes:
The Department of Health and Human Services issued a
rule granting patients direct access to lab test results by
removing the legal barriers that have prevented medical
laboratories from providing lab test results directly to pa-
tients or their designees.34
In the spring of 2015, the Food and Drug Administration
revised its guidance for communicating risks in direct-
to-consumer (DTC) advertising, recommending the use of
nontechnical language (eg, drowsiness rather than somno-
lence) and clear, everyday prose that describes risks as well
as benefits. New DTC Guidance treats consumers as people
who deserve to know about the compounds that they take
into their bodies.35
The pace of patient engagement technology is accelerat-
ing at an unprecedented rate.
 Virtual consults – especially appealing to patients with
depression – are expected to double by 2020, leading to
potential growth in reimbursement.36
 Start-ups are vying to build an ‘‘Uber’’ for health care
whereby the closest provider will come and care for the
patient.37 On-Demand Doctor start-ups are putting a
high-tech spin on old-fashioned house calls; for in-
stance, in New York City and San Francisco, a pager
will dispatch a doctor or nurse via Uber for $200 per
urgent-care visit and $75-$100 per wellness check.
 In some rural California facilities, ‘‘live’’ hospital
rounds are being made remotely by a San Francisco-
based physician using a robot.38
 Wearable technology to monitor health raises the ques-
tion, ‘‘Will primary care become a self-administered
system?’’ What apps might be created to assist patients
with depression?
Patient-centered provisions of the ACA promote care that
is delivered at home by the family. New York recently be-
came the 15th state to enact legislation requiring hospitals to
include a patient-designated care partner in the patient’s
care plan. Hospital staff are required to notify and offer to
meet with the care partner, discuss the patient’s care plan
prior to discharge, and offer adequate training in aftercare
tasks. In recognizing and involving the 4.1 million New
Yorkers who serve as care partners, the Caregiver Advise,
Record, Enable Act may also reduce the $17 billion spent
annually by Medicare on avoidable readmissions.39
Incentives are aligning at the macro level as well: for
example, the Institute of Medicine developed a national
network of patient and family leaders in 2015 to drive
system change40; the Centers for Medicare and Medicaid
Services (CMS) Partnership for Patients set hospital en-
gagement priorities in 2013/201441; and, the ACA included
PCMHs, ACOs, Medicare Shared Savings Programs, and
meaningful use thresholds.42 All of these have patient en-
gagement requirements and all recognize the issues and
quality gaps in BH.
Health reform builds on the concept of BH parity. It
recognizes that those with the highest health care utilization
across all payers are those with comorbid BH conditions –
mainly depression and anxiety. These populations have
difficulty focusing on and understanding clinicians’ in-
structions, tend to be suspicious of medications, and use the
emergency room excessively. ACA is funding a pilot to
change reimbursement/bundle payment, funding care man-
agement pilots, and requiring BH parity across all payers.
As different aspects of the law take effect and programs
are launched, new measures of patient experience are be-
ing introduced. In the CMS Fiscal Year 2016 value-based
purchasing domains, patient experience of care accounts
for 25% of the base operating diagnosis-related group
payment reduction amount (ie, 8 patient experience mea-
sures – 7 Hospital Consumer Assessment of Healthcare
Providers and Systems composites and 1 global measure).43
Although a validation process is yet to be implemented,
the National Committee for Quality Assurance added the
following BH elements to its standards for PCMH in
2014:44
1) Depression screening for adults and adolescents using
a standardized tool as part of the comprehensive health
assessment.
2) Clinical decision support and evidence-based guide-
lines for a mental health disorder or substance use
disorder.
3) A referral process for arranging or providing treatment
for mental health and substance abuse disorders.
Improving quality of care and health outcomes
for patients with depression
Distressed patients use health care twice as often those
patients who are not distressed, and most BH care is de-
livered in primary care settings. Irrespective of care setting,
BH care typically fails to achieve the desired outcomes
because most patients only have a single visit.
The integrated primary care team is a new paradigm
wherein all team members (ie, the patient, PCP, medical
assistant, nurse care manager, family, social worker, BH
provider, pharmacist, and community) are vital to patient
outcomes. It does not replace specialty care – rather, pa-
tients with more severe conditions are referred for specialty
care. Colocation of primary care and mental health provid-
ers in the same building does not constitute integrated ser-
vices. A key feature of integrated care is that the timing and
setting of visits are decided by the patient. Patient visits can
be by phone, computer, or on a patient’s day off from work,
among other alternatives.
IMPROVING OUTCOMES FOR PATIENTS WITH DEPRESSION S-7
Recovery requires taking medication, changing medica-
tion if there are side effects, and obtaining additional be-
havioral information when needed. Because adherence to
treatment is more difficult for patients with a BH diagnosis,
caregiver support is an important element of integrated care.
For instance, a psychoeducation program is available to
assist caregivers of patients with significant dementia. Stu-
dies show that patients with alcohol dependence respond
better to treatment provided in the primary care setting be-
cause providers are more engaged with patients.45 Disease
management for BH conditions is promising as well; most
programs utilize 3- to 6-month interventions.
Currently, a number of models are used to integrate BH
into primary care.
1) Collaborative Care Model (CCM) - examples include:
B Improving Mood – Providing Access to Collabora-
tive Treatment (IMPACT) http://impact-uw.org/
B Depression Improvement across Minnesota Offering
a New Direction (DIAMOND) http://www.integration
.samhsa.gov/images/res/DIAMONDWhitePaper
200807211.pdf
B Care of Mental, Physical and Substance Use Syn-
dromes (COMPASS) http://www.prhi.org/initiatives/
compass
B Washington State Mental Health Integration Pro-
gram serving 45,000 clients across the state. Oper-
ated by the University of Washington through
Federally Qualified Health Centers (FQHCs), this is
a CCM with an on-site collaborative care coordi-
nator. https://aims.uw.edu/washington-states-mental-
health-integration-program-mhip
2) Comprehensive Primary Care Model – eg, Sustaining
Healthcare Across Integrated Primary Care Efforts
(SHAPE) at Colorado’s Rocky Mountain Health Plan
http://sustainingintegratedcare.net/
3) Combined FQHC and Community Mental Health
Centers (CMHC) combinations – eg, FQHC and Cher-
okee Health System CMHC https://integrationacademy
.ahrq.gov/content/Cherokee%20Health%20Systems
4) FQHC/CMHC Partnerships
B Primary and Behavioral Health Care Integration
funded programs in Missouri and Michigan
B Integrated Comprehensive Health Systems at Inter-
mountain Healthcare and Group Health of Puget
Sound
5) The Commonwealth of Pennsylvania Regional In-
tegrated Program (under the auspices of the Pharma-
ceutical Assistance Contract for the Elderly/Needs
Enhancement Tier program) wherein all patients with
a diagnosis of depression are prescribed an antipsy-
chotic, anxiolytic or antidepressant medication.
CCM is a model that shows great promise. A CCM care
team that includes the PCP, a mid-level care manager on
site, and a consulting psychiatrist provides measurement-
based treatment to defined targets, and monitors identified
patient populations in a registry. Extensive evidence (80+
randomized controlled trials) demonstrates improved patient
outcomes and cost savings.46
Although variable across settings, integrated care doubles
the effectiveness of care for patients with depression.47
IMPACT replication studies show that the model is robust
across population segments and comorbid conditions, and
that integrated care reduces health care costs ($6.50 saved
per $1 invested over 3 years). Implementing CCM requires
leadership and workforce training and a holistic system is
essential for achieving savings (ie, the patient and the em-
ployer experience return on their investment whereas the
hospital does not experience savings).48
Chief among the challenges for implementation of CCM
for depression is scalability; 1 or 2 patients a day is insuf-
ficient volume to house a BH professional on site. Psy-
chiatry is too expensive for the average primary care
practice, and there is little return on investment for health
systems. With approximately 14 full-time equivalent BH
professionals in its large system, the Philadelphia Veterans
Administration (VA) is ideally suited to collaborative care.
The VA has the ability to track patients via a fully integrated
medical record and registry-based care. The VA medical
record becomes a life record, and showing a patient a gra-
phic representation of his/her condition is worth a thousand
words. There are patient-level reports and data can be used
for comparative effectiveness, patient profiling, clinic pro-
filing and provider profiling. Reports track provider work-
load and outcomes. The success of the VA BH provider can
be traced to the ability to track down patients in person or
via phone to remind them to return for a session.
CCM strategies include a focus on developing practice-
based evidence to facilitate continual improvement over
time. Using a measurement-based treatment to target pro-
cess, medications and other treatments are actively manip-
ulated until the patient’s clinical goals are achieved.
Changing the cost of care discussion
from how much to how well
Despite unequivocal evidence of clinical benefit, sub-
stantial underutilization of high-value services persists
across the spectrum of clinical care. The conversation must
change from how much money we spend to how well we
spend it. Ideally, consumer cost-sharing levels should be set
to encourage clinically appropriate use.
The current ‘‘one size fits all’’ cost-sharing approach fails
to acknowledge substantial differences in clinical value among
medical interventions. Trends show that the most vulnerable
consumers are the most likely to suffer (eg, they buy a health
insurance plan they can afford but later find that BH is not
covered). Studies among Medicare patients with depressive
symptoms show a disturbing pattern of cost-related non-
adherence to treatment and subsequent worsening of symptoms.
Consumer engagement solutions are necessary to better
allocate health expenditures based on the clinical benefit—
not just the cost—of services. One potential solution to cost-
related nonadherence is ‘‘clinically nuanced cost-sharing.’’
The tenets of clinical nuance recognize that (1) medical
services differ in the amount of health produced, and (2) the
clinical benefit derived from a specific service is influenced
by the individual consumer using it as well as where and
when the service is provided.
Employers must spend wisely and demand an insurance
design that improves employee health. All stakeholders
benefit from Value-based Insurance Design (VBID): con-
sumers have better access and lower out-of-pocket costs,
payers promote efficient expenditures and reduce wasteful
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spending, and providers enhance their patients’ health out-
comes in alignment with performance measures.
Although access to preventive services has been ex-
panded since implementation of the ACA, there are serious
unresolved issues. For instance:
 Preventive screenings are covered for certain condi-
tions but treatment for the condition is not.
 No distinction in coverage and cost-sharing is made
between care that is evidence based and care that is not.
Strengthening Medicare Advantage Through Innovation
and Transparency, a bill seeking to direct the department of
Health and Human Services to establish a VBID demon-
stration for Medicare Advantage beneficiaries with chronic
conditions, recently passed the US House with strong bi-
partisan support.49 Building on momentum from Congres-
sional support, CMS will begin a 5-year demonstration
program of VBID in Medicare Advantage plans in 2017.
Programs in 8 states (Pennsylvania, Tennessee, Oregon,
Massachusetts, Iowa, Rhode Island, Connecticut, and Del-
aware) and the District of Columbia will test the utility of
structuring consumer cost sharing and other health plan
design elements to encourage patients to use high-value
clinical services and providers. One of the targeted clinical
conditions is mood disorders and a population-level status
report on the collective experience of these states could shed
light on this key area.
Another potential solution is the ‘‘high-value health plan’’
that permits coverage of additional evidence-based services
prior to meeting a plan deductible in Health Savings
Account-qualified High Deductible Health Plans.
Supply side initiatives (eg, provider incentives via pay-
ment reform, pay for performance, bundled payments) often
pay little attention to consumer decision making or the
‘‘demand side’’ of care-seeking behavior. We are allowing
patients to enroll in health plans that make it increasingly
difficult to get the care they need. If providers are being paid
to screen for depression, patients must have access to ef-
fective and affordable treatment options. Using clinical
nuance to align payment reform and consumer engagement
initiatives can help improve quality of care, enhance patient
experience, and contain cost growth.
Like other chronic illnesses, BH conditions often require
multiple therapies to achieve the desired clinical outcomes
for individual patients. Rather than imposing administrative
and financial barriers to access to additional therapies, a
dynamic approach to benefit design lowers consumer cost
sharing for individuals who diligently follow the necessary
steps for managing their conditions and enhances access to
clinically appropriate therapies.
VBID has proven effective for chronic physical condi-
tions (eg, low- or no-cost foot and eye examinations and
glucose control agents for patients with diabetes). There
likely is a role for VBID in improving health outcomes and
lowering costs for mood disorders.
Panel Insights and Recommendations
There was consensus among the expert panelists that a
massive amount of work looms ahead. At the most funda-
mental level, all stakeholders must actively advocate to
dismantle the historically separate siloes of physical and
mental health, consolidate all resources, eliminate carve-
outs, and improve communication and collaboration. There
was general agreement regarding the urgent need for solu-
tions aimed at optimizing BH outcomes and promoting
value-based approaches at the population health level. To
accomplish this, there must be a paradigm shift in percep-
tion across all sectors; public policy makers, medical edu-
cators, the health care industry, business organizations, and
the community must come to terms with the reality that the
population with BH conditions is not at fault. The problems
are systemic and the solutions lie in better understanding
and addressing them.
Two organizations were recognized as being at the fore-
front of positive change. Established as a national resource
center in 2000 with funding from the Agency for Healthcare
Research and Quality, the Academy for Integrating Beha-
vioral Health and Primary Care provides access to literature
and integrated BH quality measures. The National Alliance
on Mental Illness, the nation’s largest mental health advo-
cacy organization, plays a valuable role in raising aware-
ness, identifying needs, and providing support and guidance
for individuals and educators.
Panelists made observations and recommendations on a
broad scope of interrelated issues.
Diagnosis and treatment of depression: Mood vs. de-
pression is almost impossible to discern in the primary care
setting. Clinicians need better guidance for distinguishing a
treatable condition (mood disorder) from depression. For
example, when there is a death in the family a patient may
be sad but still functioning. We must clearly define major
depression and develop simple tools to help distinguish it
from a situational response to life events and stresses. The
pharamacogenetic challenge is selecting the right antide-
pressant for each patient. There is potential for using the
genome to assess risk and personalize approaches to treat-
ment of depression.
Patient and family engagement: Successful primary care
practices believe that everyone is part of the team and the
practice’s structure reflects this. Patients and families can be
enormously helpful if they are viewed as part of the treat-
ment plan design. The dialog becomes:
Patient: ‘‘I am an expert about me.’’
Provider: ‘‘I am listening to you.’’
Clinicians should view a screening tool as an alert—a
sign that something new or different should be done (eg,
pharmaceutical, behavior modification). The entire team—
including the patient and caregivers—must understand how
cognition impacts daily life. A common vocabulary (all
ethnic groups) is essential for conversations that help iden-
tify problems. Checklists are a vital element and everyone
on the team can play a role.
Patient and family preferences must be taken into account
in integrated approaches across all settings. This involves
providing appropriate resources to train clinical and non-
clinical staff in skills necessary for empathy and active
listening, and a sound approach to specific goal setting and
measurement (eg, 90% of the staff will receive empathy
training by August 2017).
Typically, BH screening is oriented toward giving infor-
mation to the provider rather than to the patient and family.
When the patient and family are engaged and informed, it is
more difficult for them to ignore the screening test results.
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Performance measurement and quality improvement: All
stakeholders need targeted, evidence-based tools to identify,
treat, and monitor BH conditions. Measures of patient per-
formance as well as clinician performance are vital for as-
suring that BH conditions such as depression receive much
needed attention. For example, the Medicare Shared Savings
goal is not just to identify a condition but also to get to
remission. Accountability for population health measure-
ment and evaluation should be factored into new models of
care in order to learn what works and what does not.
Vague answers to questions like, ‘‘How are you doing?’’
are insufficient. BH must develop its own set of consistent
measures of BH status and outcomes, comparable to the
‘‘vital signs’’ used in physical health care. There are too few
BH quality measures, and too many of those that exist assess
processes rather than outcomes. Aggressive quality im-
provement strategies will help make treatment systems more
effective.
Cognition might be considered to be a new BH health
outcome measure and incorporated into a population health
strategy for identifying which patients need treatment and
follow-up. Recovery is another key outcome; it is very
important to involve the patient in defining recovery.
Provider reimbursement: Public and private payers must
determine how to reimburse BH providers for novel treat-
ments and care delivery models. For instance, because tel-
emedicine has shown promise for managing patients with
depression, funding should be considered for team-based
care delivery via telehealth.
The discussion of VBID in the context of BH revealed
that benefit designs should not be approached in a ‘‘one size
fits all’’ fashion. Hospital administrators should negotiate
with insurers to create benefit designs wherein pricing re-
flects the value a particular service brings to its patients and
the system. VBID has great potential as a powerful tool for
aligning what we spend with what has real value for patients
and populations with depression.
Technological issues: To date, health information tech-
nology applications for the BH setting have been disap-
pointing and/or inadequate. Aside from the VA, electronic
health records (EHRs) rarely address the full range of
medical, behavioral, and socioeconomic factors or share
information easily. Registries are not a regular feature of
EHR systems, making it difficult to monitor patient popu-
lations. Health information exchange is still very limited,
especially for BH information. Privacy laws are often con-
strued as barriers to such information exchanges; this is
especially true for substance abuse. Such rules are outdated
and counterproductive.
Provider liability: Panelists concurred that if a provider
does not have the ability to treat depression, he or she
generally does not ask about it. The liability issues asso-
ciated with asking must be built into the care delivery
model.
Conclusion
National statistics confirm that depression is a serious and
growing population health issue. Like other chronic condi-
tions, effective treatment is long term and must go well
beyond clinical sessions and prescriptions to address issues
such as adequate housing and jobs; however, this is where the
similarity ends. Long-standing, complex problems continue
to hamper efforts to provide high-value care for BH disor-
ders. The traditionally separate physical health and BH
systems have long hampered the delivery of appropriate,
cost-effective care, and the acute care model—writing a
prescription and moving on—does not foster the develop-
ment of caring relationships among providers, patients, and
their families. A chronic shortage and inequitable distribu-
tion of well-trained BH providers is another concern.
On November 3, 2015, a multidisciplinary panel of ex-
perts met to discuss these critical issues and share infor-
mation about opportunities for improving individual patient
and population health outcomes for depressive disorders.
Multistakeholder approaches, integrated care delivery sys-
tems, and VBID were discussed as methods to reduce
fragmentation in care settings and reimbursement structures.
Importantly, the panelists recommended targeted educa-
tion for PCPs, employers, patients, and families to promote
better understanding of depression.
There was consensus among the panelists that health re-
form has made progress in removing some of the barriers to
care and paved the way for new approaches to medical
management of patients suffering from depression. The
Triple Aim calls for better care, better experience of care,
and lower cost; panelists observed that ‘‘for the patient and
family’’ should be added to each of these aims.
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